STOCK TITAN

Inogen Inc - INGN STOCK NEWS

Welcome to our dedicated news page for Inogen (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inogen's position in the market.

Rhea-AI Summary
Inogen completes acquisition of Physio-Assist, expanding respiratory portfolio with Simeox device for bronchiectasis treatment. Acquisition expected to be immaterial to 2023 revenue and immediately accretive to gross margin. Simeox has CE mark in EU and is being sold in Europe, Asia, and Middle East. Inogen to pursue US regulatory approvals. Acquisition may provide access to large US market with 400,000 to 490,000 bronchiectasis patients. Transaction expected to be accretive to adjusted earnings starting in 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
News
Rhea-AI Summary
Inogen appoints Mike Sergesketter as Interim CFO and reaffirms 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.6%
Tags
Rhea-AI Summary
Inogen, Inc. (Nasdaq: INGN) introduces the Rove 6™ portable oxygen concentrator in the US with an 8-year expected service life, extending to Inogen One® G5. The Rove 6 offers 6 settings, the longest battery life in the market, and delivers up to 1,260 mL/minute of medical grade oxygen at a weight of 4.8 pounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
management
Inogen Inc

Nasdaq:INGN

INGN Rankings

INGN Stock Data

171.69M
21.19M
0.92%
93.79%
7.23%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Goleta

About INGN

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take